Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

15 recalls · Class I, newest first

Class I · High risk

Dyural-80 Injection Kit

Labeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating stoppers do not contain latex. The stoppers contain natural rubber latex

Terminated Labeling / mix-up Asclemed USA Inc. dba Enovachem NDC 76420-0755-01 D-0354-2019
Class I · High risk

Dyural-40 Injection Kit

Labeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating stoppers do not contain latex. The stoppers contain natural rubber latex

Terminated Labeling / mix-up Asclemed USA Inc. dba Enovachem NDC 76420-0750-01 D-0353-2019
Class I · High risk

Phenylephrine HCl

Labeling: Label Error on Declared Strength: Label incorrectly lists concentration as "10 mcg per mL" rather than the correct concentration of "100 mcg per mL".

Terminated Labeling / mix-up Advanced Pharma Inc. D-0347-2019
Class I · High risk

Sodium Chloride Injection

Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also incorrectly state that the stoppers do not contain latex. The above listed product codes and batches being recalled have stoppers containing natural rubber latex.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-186-20 D-0299-2019
Class I · High risk

Sodium Chloride Injection

Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect statement on the product insert for product codes 918610 and 918620 indicating that the stoppers do not contain natural rubber latex. The tray label for these two product codes and the vial label for product code 918620 also incorrectly state that the stoppers do not contain latex. The above listed product codes and batches being recalled have stoppers containing natural rubber latex.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-186-10 D-0298-2019
Class I · High risk

Levetiracetam in 0.54 % Sodium Chloride Injection 1

Labeling: Label Error on Declared Strength; the pre-printed text on the primary infusion bag and the NDC incorrectly identifies the product as Levetiracetam in 0.75% Sodium Chloride (1000 mg/100 mL) however, the external foil pouch correctly identifies the product as Levetiracetam in 0.54% Sodium Chloride Injection (1,500/100 mL).

Terminated Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-637-52 D-0485-2019
Class I · High risk

robaxin-750

Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct dosage of "Two tablets three times daily."

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 52244-449-10 D-0009-2019
Class I · High risk

Hydrochlorothiazide Tablets USP

Product Mix-Up: customer complaint that a sealed bottle labeled as Hydrochlorothiazide Tablets USP 12.5 mg contained only Spironolactone Tablets USP 25 mg.

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-182-01 D-1206-2018
Class I · High risk

Montelukast Sodium Tablets 10 mg

Labeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg.

Ongoing Labeling / mix-up Hetero Labs Limited Unit V NDC 31722-726-30 D-0081-2019
Class I · High risk

Neostigmine Methylsulfate Injection Solution

Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.

Terminated Labeling / mix-up Fagron Compounding Services LLC dba Fagron Sterile Services NDC 71266-2003-01 D-0911-2018
Class I · High risk

Neostigmine Methylsulfate Injection Solution

Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.

Terminated Labeling / mix-up Fagron Compounding Services LLC dba Fagron Sterile Services NDC 71266-2003-02 D-0910-2018
Class I · High risk

Senna Laxative

Labeling: Label Mix-Up: Customer complaint received that a bottle labeled as Senna Laxative contained only tablets of Naproxen Sodium 220 mg.

Terminated Labeling / mix-up Magno Humphries Laboratories, Inc D-0342-2018
Class I · High risk

Clopidogrel Tablets

LABELING: LABEL MIX-UP. Simvastatin tablets, USP 10 mg were found in bottles labeled as Clopidogrel tablets, USP 75 mg.

Terminated Labeling / mix-up International Laboratories, LLC NDC 54458-888-16 D-0472-2018

Recalls by year